Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.46 |
| ▸ | ITGAV | P06756 | 8/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034489 | 0.94 | ITGB3 (0.47) | ITGB3ITGAVITGA2BPOLBMEN1 | |
| SCHEMBL7036024 | 0.93 | ITGB3 (0.46) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7033770 | 0.93 | ITGB3 (0.53) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7034232 | 0.93 | ITGB3 (0.40) | ITGB3ITGAVITGA2BKMT2AEGLN2 | |
| SCHEMBL7038861 | 0.92 | ITGB3 (0.44) | ITGB3ITGAVITGA2BPOLBMEN1 | |
| SCHEMBL7038442 | 0.92 | ITGB3 (0.51) | ITGB3ITGAVITGA2BPOLBMEN1 | |
| SCHEMBL7029576 | 0.92 | ITGB3 (0.44) | ITGB3ITGAVITGA2BPOLBMEN1 | |
| SCHEMBL7035562 | 0.91 | NAMPT (0.53) | POLBKMT2ANAMPT | |
| SCHEMBL7248927 | 0.91 | NAMPT (0.45) | ITGB3ITGAVPOLBMEN1KMT2A | |
| SCHEMBL7036473 | 0.91 | ITGB3 (0.45) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | ITGB3 403/4885ITGAV 289/4885ITGA2B 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.